Physician profile
Aimee Jackowski
NPI 1477305548
$1,698.99
in general payments reported to CMS, 2019-2025
19 companies · $846 in 2025
The $846 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $853 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,698.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $307.66 | 2024-2025 | |
| Axsome Therapeutics, INC. | $256.70 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.17 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $155.47 | 2024-2025 | Rexulti |
| Tris Pharma INC | $116.26 | 2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $106.72 | 2024-2025 | Fanapt |
| Vertical Pharmaceuticals, LLC | $86.35 | 2024-2025 | Relexxii |
| Neurocrine Biosciences, INC. | $78.11 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $68.93 | 2024-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $68.03 | 2024 | Rexulti |
| Bausch Health US, LLC | $61.59 | 2025 | Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $53.68 | 2024-2025 | Cobenfy |
| Corium, LLC | $35.28 | 2024-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $33.59 | 2024-2025 | Austedo Xr, Austedo Xr |
| Almatica Pharma LLC | $30.16 | 2025 | Loreev Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $22.18 | 2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $19.47 | 2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $15.39 | 2024 | Quviviq |
| Noven Therapeutics, LLC | $14.25 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Jackowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.